Takeda Pharmaceutical Total Long-Term Assets 2010-2024 | TAK

Takeda Pharmaceutical total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Takeda Pharmaceutical total long-term assets for the quarter ending September 30, 2024 were $83.969B, a 6.64% decline year-over-year.
  • Takeda Pharmaceutical total long-term assets for 2024 were $86.596B, a 1.23% increase from 2023.
  • Takeda Pharmaceutical total long-term assets for 2023 were $85.542B, a 9.19% decline from 2022.
  • Takeda Pharmaceutical total long-term assets for 2022 were $94.201B, a 1.75% decline from 2021.
Takeda Pharmaceutical Annual Total Long-Term Assets
(Millions of US $)
2024 $86,596
2023 $85,542
2022 $94,201
2021 $95,874
2020 $95,235
2019 $97,395
2018 $27,249
2017 $28,785
2016 $20,337
2015 $25,263
2014 $29,766
2013 $30,256
2012 $29,185
2011 $14,460
2010 $13,445
2009 $10,257
Takeda Pharmaceutical Quarterly Total Long-Term Assets
(Millions of US $)
2024-06-30 $83,969
2024-03-31 $86,596
2023-12-31 $80,200
2023-09-30 $85,628
2023-06-30 $89,941
2023-03-31 $85,542
2022-12-31 $77,452
2022-09-30 $85,271
2022-06-30 $88,673
2022-03-31 $94,201
2021-12-31 $89,942
2021-09-30 $91,946
2021-06-30 $92,645
2021-03-31 $95,874
2020-12-31 $92,828
2020-09-30 $92,398
2020-06-30 $94,294
2020-03-31 $95,235
2019-12-31 $96,703
2019-09-30 $97,703
2019-06-30 $96,626
2018-12-31 $27,565
2018-06-30 $28,667
2017-06-30 $27,676
2016-06-30 $21,794
2015-06-30 $23,365
2015-03-31 $20,475
2014-12-31 $21,206
2014-09-30 $23,085
2014-06-30 $23,259
2014-03-31 $24,344
2013-12-31 $21,342
2013-09-30 $20,576
2013-06-30 $20,620
2013-03-31 $24,072
2012-12-31 $23,962
2012-09-30 $22,235
2012-06-30 $22,297
2012-03-31 $22,979
2011-12-31 $21,794
2011-09-30 $22,579
2011-03-31 $9,314
2010-03-31 $9,798
2009-09-30
2009-03-31 $10,257
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $42.414B $28.196B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.725B 30.68
Sandoz Group AG (SDZNY) Switzerland $19.283B 0.00
Merck (MKKGY) Germany $18.792B 16.83
Astellas Pharma (ALPMY) Japan $18.332B 16.88
United Therapeutics (UTHR) United States $16.401B 16.13
Summit Therapeutics (SMMT) United States $13.584B 0.00
Neurocrine Biosciences (NBIX) United States $12.656B 33.51
Shionogi (SGIOY) Japan $11.814B 11.32
Catalent (CTLT) United States $10.829B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.563B 7.40
Madrigal Pharmaceuticals (MDGL) United States $7.181B 0.00
Orion OYJ (ORINY) Finland $6.653B 18.71
Corcept Therapeutics (CORT) United States $5.859B 44.38
Ionis Pharmaceuticals (IONS) United States $5.359B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.289B 0.00
PTC Therapeutics (PTCT) United States $3.308B 0.00
Dyne Therapeutics (DYN) United States $3.026B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.578B 15.41
Catalyst Pharmaceuticals (CPRX) United States $2.519B 11.42
Soleno Therapeutics (SLNO) United States $2.356B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $2.272B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $2.061B 0.00
Evotec AG (EVO) Germany $1.896B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.859B 0.00
Xencor (XNCR) United States $1.687B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.648B 0.00
Harrow (HROW) United States $1.563B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.551B 0.00
Cassava Sciences (SAVA) United States $1.548B 0.00
Indivior (INDV) United States $1.484B 6.04
Guardian Pharmacy Services (GRDN) United States $1.397B 0.00
Ocular Therapeutix (OCUL) United States $1.339B 0.00
ARS Pharmaceuticals (SPRY) United States $1.300B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.256B 0.00
Enliven Therapeutics (ELVN) United States $1.242B 0.00
Ardelyx (ARDX) United States $1.213B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.124B 0.00
Collegium Pharmaceutical (COLL) United States $0.981B 5.35
Bioventus (BVS) United States $0.934B 29.51
Cronos Group (CRON) Canada $0.784B 0.00
Relay Therapeutics (RLAY) United States $0.777B 0.00
USANA Health Sciences (USNA) United States $0.750B 13.91
Oruka Therapeutics (ORKA) United States $0.717B 0.00
Elite Pharmaceuticals (ELTP) United States $0.660B 0.00
Exscientia (EXAI) United Kingdom $0.633B 0.00
Altimmune (ALT) United States $0.598B 0.00
Tourmaline Bio (TRML) United States $0.583B 0.00
Savara (SVRA) United States $0.556B 0.00
OmniAb (OABI) United States $0.544B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.534B 0.00
Organogenesis (ORGO) United States $0.533B 0.00
ProKidney (PROK) United States $0.507B 0.00
Zevra Therapeutics (ZVRA) United States $0.487B 0.00
Esperion Therapeutics (ESPR) United States $0.487B 0.00
Korro Bio (KRRO) United States $0.474B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.473B 0.00
Xeris Biopharma Holdings (XERS) United States $0.453B 0.00
Siga Technologies (SIGA) United States $0.448B 5.22
Rigel Pharmaceuticals (RIGL) United States $0.441B 178.86
Aquestive Therapeutics (AQST) United States $0.411B 0.00
KalVista Pharmaceuticals (KALV) United States $0.403B 0.00
Akebia Therapeutics (AKBA) United States $0.397B 0.00
Larimar Therapeutics (LRMR) United States $0.391B 0.00
Verve Therapeutics (VERV) United States $0.389B 0.00
4D Molecular Therapeutics (FDMT) United States $0.369B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.356B 0.00
Avita Medical (RCEL) United States $0.337B 0.00
Aclaris Therapeutics (ACRS) United States $0.309B 0.00
Sage Therapeutics (SAGE) United States $0.297B 0.00
Nature's Sunshine Products (NATR) United States $0.289B 17.21
Aldeyra Therapeutics (ALDX) United States $0.286B 0.00
Lyell Immunopharma (LYEL) United States $0.256B 0.00
Silence Therapeutics (SLN) United Kingdom $0.230B 0.00
Lexeo Therapeutics (LXEO) United States $0.205B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.204B 0.00
Acrivon Therapeutics (ACRV) United States $0.201B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.197B 0.00
Nektar Therapeutics (NKTR) United States $0.186B 0.00
Profound Medical (PROF) Canada $0.185B 0.00
MediWound (MDWD) Israel $0.181B 0.00
Nanobiotix S.A (NBTX) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.171B 0.00
Heron Therapeutics (HRTX) United States $0.161B 0.00
Achieve Life Sciences (ACHV) Canada $0.149B 0.00
CytoDyn (CYDY) United States $0.144B 0.00
VAXART, INC (VXRT) United States $0.136B 0.00
Inhibikase Therapeutics (IKT) United States $0.135B 0.00
Telomir Pharmaceuticals (TELO) United States $0.132B 0.00
Cardiol Therapeutics (CRDL) Canada $0.129B 0.00
Pyxis Oncology (PYXS) United States $0.125B 0.00
Context Therapeutics (CNTX) United States $0.113B 0.00
Journey Medical (DERM) United States $0.109B 0.00
Century Therapeutics (IPSC) United States $0.105B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Avalo Therapeutics (AVTX) United States $0.100B 0.00
Fractyl Health (GUTS) United States $0.099B 0.00
Karyopharm Therapeutics (KPTI) United States $0.097B 0.00
Assertio Holdings (ASRT) United States $0.092B 24.14
Regulus Therapeutics (RGLS) United States $0.092B 0.00
Arch Biopartners (ACHFF) Canada $0.090B 0.00
Inotiv (NOTV) United States $0.089B 0.00
PMV Pharmaceuticals (PMVP) United States $0.083B 0.00
Relmada Therapeutics (RLMD) United States $0.083B 0.00
CASI Pharmaceuticals (CASI) China $0.081B 0.00
Vivani Medical (VANI) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.078B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
Scienture Holdings (SCNX) United States $0.069B 0.00
Metagenomi (MGX) United States $0.068B 0.00
AlloVir (ALVR) United States $0.066B 0.00
ElectroCore (ECOR) United States $0.065B 0.00
OptiNose (OPTN) United States $0.060B 0.00
Champions Oncology (CSBR) United States $0.058B 0.00
Mural Oncology (MURA) Ireland $0.057B 0.00
BioVie (BIVI) United States $0.055B 0.00
Nutriband (NTRB) United States $0.055B 0.00
Unicycive Therapeutics (UNCY) United States $0.055B 0.00
Prelude Therapeutics (PRLD) United States $0.053B 0.00
Rafael Holdings (RFL) United States $0.050B 0.00
Iterum Therapeutics (ITRM) Ireland $0.049B 0.00
Protara Therapeutics (TARA) United States $0.047B 0.00
SCYNEXIS (SCYX) United States $0.045B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.045B 0.00
Gain Therapeutics (GANX) United States $0.043B 0.00
VYNE Therapeutics (VYNE) United States $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.041B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Tempest Therapeutics (TPST) United States $0.039B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.038B 0.00
CERo Therapeutics Holdings (CERO) United States $0.037B 0.00
Carisma Therapeutics (CARM) United States $0.035B 0.00
Incannex Healthcare (IXHL) Australia $0.035B 0.00
Surrozen (SRZN) United States $0.030B 0.00
Citius Pharmaceuticals (CTXR) United States $0.030B 0.00
DURECT (DRRX) United States $0.027B 0.00
Lipocine (LPCN) United States $0.027B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.026B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
BioLineRx (BLRX) Israel $0.026B 0.00
GlycoMimetics (GLYC) United States $0.021B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
ProPhase Labs (PRPH) United States $0.019B 0.00
Enlivex Therapeutics (ENLV) Israel $0.018B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.015B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Traws Pharma (TRAW) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.013B 0.00
Lyra Therapeutics (LYRA) United States $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
Jaguar Animal Health (JAGX) United States $0.012B 0.00
Conduit Pharmaceuticals (CDT) United States $0.011B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Klotho Neurosciences (KLTO) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Ainos (AIMD) United States $0.006B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Biomerica (BMRA) United States $0.005B 0.00
Aditxt (ADTX) United States $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Aptorum Group (APM) United Kingdom $0.004B 0.00
TNF Pharmaceuticals (TNFA) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
Bio-Path Holdings (BPTH) United States $0.003B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 2.13
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.47